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Introduction
Approximately 2.7 to 6.1 million patients suffer from atrial 
fibrillation (AF) in USA.1 The incidence rate has been estimated to be 
approximately 0.4%, which continues to grow with aging population, 
improvement in medical therapies and longer survival with heart 
disease.2 Since Haïssaguerre’s seminal observation identifying 
pulmonary veins as triggers for AF, there has been a dramatic increase 
in the number of patients undergoing catheter-based pulmonary 
vein isolation over the past 15 years.3 In 2012, the Heart Rhythm 
Society/ European Heart Rhythm Association/ European Cardiac 
Arrhythmia Society issued a Class I recommendation for catheter 
ablation in patients with antiarrhythmic refractory symptomatic 
paroxysmal AF and class IIa recommendation in patients with 
symptomatic AF prior to initiating antiarrhythmic therapy.4 Despite 
scientific advancements in mapping and catheters for radiofrequency 
(RF) ablation, data from multicenter registries have shown that 
only about 75% of patients with paroxysmal AF achieve durable 
maintenance of sinus rhythm.3 These observations have catalyzed the 
development of alternative techniques and energy sources for catheter 
ablation with the aim of simplifying the procedure and improving 
outcomes. The conventional RF ablation using irrigated catheter has 
also evolved from its point-by-point approach to circumferential 
approach and now includes contact-sensing and phased duty-cycled 
RFA technology. A recent network meta-analysis by Kabunga et 
al explored the 3 most commonly used AF ablation strategies to 
compare outcomes of RFA using conventional irrigated catheter, 
phased duty-cycled RFA, and cryoballoon ablation (CBA). However, 
since their report, 7 additional prospective and randomized trials have 
been added to the literature comparing RFA and CBA. We aimed to 
compare the efficacy, procedural characteristics and complications of 
both the approaches and provide with the most updated evidence on 
this topic.
Methods
www.jafib.com Oct-Nov 2016| Volume 9| Issue 3
Abstract
Introduction: We aimed to study the procedural characteristics, efficacy and safety of cryoballoon ablation (CBA) versus radiofrequency 
ablation (RFA) for catheter ablation of paroxysmal atrial fibrillation (AF).
Methods: A systematic literature search was performed using PubMed, EMBASE, Web of Science, and Cochrane Central Register of 
Controlled Trials to clinical trials comparing CBA and RFA for AF. Outcomes were evaluated for efficacy, procedure characteristics and safety. 
For each study, odd ratio (OR) and 95% confidence intervals (CIs) were calculated for endpoints for both approaches.
Results: We analyzed a total of 9,957 participants (3,369 in the CBA and 6,588 in RFA group) enrolled in 16 clinical trials. No significant 
difference was observed between CBA and RFA with regards to freedom from atrial arrhythmia at 12-months, recurrent atrial arrhythmias or 
repeat catheter ablation. CBA group had a significantly higher transient phrenic nerve injury (OR 14.19, 95% CI: 6.92-29.10; p<0.001) and 
persistent phrenic nerve injury (OR 4.62, 95% CI: 1.97-10.81; p<0.001); and a significantly lower pericardial effusion/cardiac tamponade 
(OR 0.43, 95% CI: 0.26-0.72; p=0.001), and groin site complications (OR 0.60, 95% CI: 0.38-0.93; p=0.02). No significant difference was 
observed in overall complications, stroke/thromboembolic events, major bleeding, and minor bleeding.
Conclusion: CBA was non-inferior to RFA for catheter ablation of paroxysmal AF. RF ablation was associated with a higher groin 
complications and pericardial effusion/cardiac tamponade, whereas CBA was associated with higher rates of transient and persistent 
phrenic nerve injury.
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The present review was performed according to Cochrane 
Collaboration and Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statements.
Search Strategy  
We performed electronic searches on PubMed, The Cochrane 
Library, EMBASE, EBSCO, Web of Science and CINAHL 
databases from the inception through April 14, 2016 to identify 
trials comparing RFA and CBA in patients with paroxysmal AF. 
We combined the terms (“radiofrequency”) AND (“cryoballoon” OR 
“cryoablation”) AND (“atrial fibrillation”) as keywords or medical 
subject heading terms. All references of the retrieved articles were 
reviewed for further identification of potentially relevant studies. The 
identified studies were systematically assessed using the inclusion 
and exclusion criteria described below.
Eligibility Criteria   
The eligibility criteria for our systematic review and meta-analysis 
included
1. Human subjects undergoing catheter ablation for paroxysmal 
AF using conventional RFA, CBA, or phase-duty cycled RFA.
2. Reported clinical outcomes, procedure time and complications.
3. Literature published in English.
4. Either randomized controlled trials (RCTs) or prospective 
cohort studies. Studies that did not have randomized or matched 
cohorts were excluded. Retrospective studies, abstracts, case reports, 
conference presentations, editorials, reviews, and expert opinions 
were excluded. We used the longest available follow-up data from 
individual studies for our analysis. All the data was extracted and 
jadad score calculated independently by 2 reviewers ( JG and RC). 
Discrepancies between the two reviewers were resolved by discussion 
and consensus. Final results were reviewed by senior investigator 
(AN) (Figure 1).
Outcomes  
The primary efficacy outcome in our study was “freedom from any 
atrial arrhythmia at 12 months”, “recurrent atrial arrhythmias”, and 
“need for repeat ablation”. Studies reporting only acute procedural 
success rates were excluded from efficacy analysis. Secondary 
procedural outcomes included “procedural time” and “fluoroscopy 
time”.
The primary safety outcome was the combined endpoint of “all-
cause mortality”, “overall complications”, “stroke or thromboembolism 
event”, “major bleeding”, “minor bleeding”, “groin site complications 
(including arteriovenous fistulae, pseudoaneurysms and hematomas 
requiring any intervention or prolonged hospital stay)”, “transient 
phrenic nerve injury” (resolved immediate post-procedure), “persistent 
phrenic nerve injury”, “pericardial effusion or cardiac tamponade” 
(requiring intervention), “atrio-esophageal fistula”, and “pulmonary 
vein stenosis”. For analysis, the conventional and duty-phased RFA 
strategies for ablation were grouped together in the RFA group.
Statistical Analysis  
Random effects model was used to estimate the odds ratio (OR) 
and respective 95% confidence intervals (CI) using Cochrane 
Collaborative software, RevMan 5.3. Measure of heterogeneity 
between the studies was assessed using the chi square test and was 
considered significant if I2>50%. All p values were 2-sided, and p 
value of <0.05 was considered significant.
Quality Appraisal And Publication Bias  
Assessment of risk of bias for each selected study was performed 
according to PRISMA 2009 guidelines. Qualitative evaluation of 
bias using the following key parameters were performed for each 
Figure 1: Process of study selection for randomized and prospective trials (PRISMA Statement)
Figure 2:
Forest plot demonstrating primary efficacy outcomes in 
patients with atrial fibrillation undergoing cryoablation versus 
radiofrequency ablation Figure 3:
Forest plot demonstrating procedural outcomes of cryoablation 
versus radiofrequency ablation
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study:
1. Clear definition of study population.
2. Clear definition of outcomes and outcome assessment.
3. Independent assessment of outcome parameters.
4. Sufficient duration of follow-up.
5. Selective loss during follow-up.
6. Important confounders and prognostic factors identified.
Evidence of publication bias was investigated visually using funnel 
plots and analyzed using Egger and Begg methods.
Results
A total of 88 studies were identified after exclusion of duplicate 
or irrelevant references (Figure 1). After a detailed evaluation of 
these studies, 16 relevant studies were included, that incorporated 
a total of 9,957 participants (3,369 in the CBA and 6,588 in RFA 
group) undergoing catheter ablation for paroxysmal AF. Of these, 5 
were RCTs5-9 and 11 were prospective observational studies.11-20 The 
characteristics of these trials, mean follow-up periods and mode of 
arrhythmia detection are described in Table 1.
Quality Assessment And Publication Bias  
Overall, there were clear definitions of the study population, 
outcomes, and assessment in most component studies, but blinded 
assessment of outcomes was not reported in all studies resulting in 
potential bias. Jadad score was calculated for all RCTs with a mean 
Jadad score of 3 indicating that the studies involved were of high 
quality (Table 1). No significant publication bias was observed 
using funnel plots (Egger’s test and Begg’s test had p values >0.05 
for all analyses) (Supplementary appendix Table 1, Supplementary 
appendix, Figure 1).
Baseline Characteristics  
In the participant studies, there were no significant differences 
between the two groups in terms of age, gender, body mass index, 
left ventricular ejection fraction (LVEF), hypertension or coronary 
artery disease. A higher prevalence of diabetes was observed (p<0.05) 
Figure 5A:
Forest plot demonstrating safety outcomes - overall acute 
complications, stroke/thromboembolism, major bleeding, 
minor bleeding and groin site complications in patients with 
atrial fibrillation undergoing cryoablation versus radiofrequency 
ablation
Figure 5B:
Forest plot demonstrating safety outcomes - transient and 
unresolved phrenic nerve injury, and pericardial effusion/
tamponade in patients with atrial fibrillation undergoing 
cryoablation versus radiofrequency ablation
Figure 4: Forest plot demonstrating all-cause mortality in patients with atrial fibrillation undergoing cryoablation versus radiofrequency ablation
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in CBA group whereas left atrial diameter (LAD) and stroke or 
thromboembolic events were significantly greater in patients with 
RFA group. No significant heterogeneity was observed for stroke 
and diabetes. However, a significant heterogeneity was observed in 
LAD (Table 2). On sub-analysis of LAD only in prospective trials, 
the standard mean difference was found to be -0.13 (95% CI -0.26 to 
-0.001; p=0.04) with no significant heterogeneity (I2=1.05).
Assessment of Efficacy  
The clinical outcomes were assessed off anti-arrhythmic therapy 
in 7 trials,5-8,14-16 on anti-arrhythmic therapy in 4 trials10-12,18 and this 
information was not available for 5 trials.9,13,17,19,20 No significant 
difference was observed between CBA and RFA in freedom from 
Supplementary 
Figure 1:
Funnel plots evaluating publication bias in all studies: a) 
Freedom from atrial arrhythmias at 12 months; b) Recurrent 
atrial arrhythmias; c) Repeat ablation within 12 months since 
index ablation; d) Overall acute complications
Table 1: Characteristics of the included studies
Name of Study Year Type of trial Cryoballoon characteristics CBA, n Radiofrequency characteristics RFA, n Follow-up 
duration (mean, 
months)
Mode of follow-up for 
arrhythmia detection
Jadad Score
Generation Size Type of RFA Approach for 
ablation
Kuck et al 2016 RCT CB-1;CB-2 23 and 28 mm 374 C - IRF point by point 376 18 months 24h Holter monitor 3
Hunter et al 2015 RCT CB-1 23 and 28 mm 78 C - IRF point by point 77 12 months 7 day Holter 3
Luik et al 2015 RCT CB-1 23 and 28 mm 156 C-IRF NS 159 12 months 7 day Holter or event 
recorder
3
P é r e z -
Castellano et al
2014 RCT CB-1 23 or 28 mm 25 C-IRF point by point 25 12 months Insertable cardiac 
monitor
3
Schmidt et al 2013 RCT NS 28 mm 33 C-IRF NS 33 NS NS 3
Khoueiry et al 2016 P; OS CB-1; CB-2 28 mm 311 C-IRF and CS-IRF Circumferential 
PVI
376 14 months 24h Holter monitor NA
Schmidt et al 2016 P; OS NS 23 and 28 mm 607 C-IRF NS 1699 12 months 12 lead ECG NA
Straube et al 2016 P; OS NS 23 and 28 mm 193 C-IRF and CS-IRF NS 180 17 months 24h Holter monitor NA
Squara et al 2015 P; OS CB-2 23 and 28 mm 178 CF-IRF Circumferential 
PVI
198 12 months 24h Holter monitor NA
W a s s e r l a u f 
et al
2015 P; OS CB-1; CB-2 23 and 28 mm 101 C-IRF NS 100 12 months 24h to 48h Holter 
monitor
NA
Jourda et al 2015 P; OS CB-2 NS 75 CF-RFA NS 75 12 months 24h Holter monitor NA
Knecht et al 2014 P; OS CB-1 23 or 28 mm 71 C-IRF Circumferential 
PVI
71 28 months 7 day Holter NA
Mugnai et al 2014 P; OS CB-1 28 mm 136 C-IRF Circumferential 
PVI
260 23 months 24h Holter monitor NA
Schmidt et al 2014 P; OS NS 23 or 28 mm 905 C-IRF NS 2870 NS NS NA
Gaita et al 2011 P; OS CB-1 23 or 28 mm 36 C-IRF point by point 36 NS NS NA
Kojodjojo et al 2010 P; OS CB-1 28 mm 90 C-IRF Circumferential 
PVI
53 14 months 24h Holter monitor NA
CBA= Cryoballoon ablation; RFA= Radiofrequency ablation; RCT=Randomized Controlled trial; P;OS = Prospective Observational Study; CB-1 = Cryoballoon 1st generation; CB-2= Cryoballoon 2nd 
generation; NS=Not specified; C-IRF= Conventional Irrigated Radiofrequency catheter; PRF= Duty-cycled phased radiofrequency; CS-IRF=contact sensing-radiofrequency; PVI=Pulmonary Vein Isolation
Supplementary 
Figure 2:
Forest plot demonstrating primary efficacy endpoints 
(randomized controlled trials only) in patients with atrial 
fibrillation undergoing cryoablation versus radiofrequency 
ablation
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Cryoablation and Radiofrequency ablation had comparable rates 
of freedom from atrial arrhythmia (OR: 1.16, 95% CI: 0.55-2.46; 
I2=70%), recurrent atrial arrhythmias (OR: 1.22, 95% CI: 0.52-2.87; 
I2=57%) and need for a repeat ablation (OR: 1.06, 95% CI: 0.65-
1.75; I2=19) (Supplementary appendix, Figure 2).
Assessment of Procedural Duration
Cryoablation group was associated with increased total fluoroscopy 
time (Standard mean difference 0.28, 95% CI: 0.06 - 0.49; I2=16%) 
and similar total procedural time (Standard mean difference: 
0.37; 95% CI: -0.52 – 1.26; I2=93%) compared to RFA group 
(Supplementary appendix, Figure 3).
Assessment of Safety and Complications
The overall complications were similar in both the groups (10.11% 
atrial arrhythmia at 12-months follow-up (OR 1.13; 95% confidence 
interval [CI]: 0.96-1.33), recurrent atrial arrhythmias (OR 1.03; 
95% CI 0.89-1.20) or repeat ablation (OR 0.83; 95% CI 0.61-1.12) 
(Figure 2). No significant heterogeneity was observed.
Assessment of Procedural Duration  
The total procedure time was not significantly different between 
CBA and RFA groups (Standard mean difference [SMD] 0.02, 95% 
CI -0.52 to 0.55; I2=98%). Similarly, the total fluoroscopy time was 
not significantly different between the two groups (SMD 0.01, 95% 
CI -0.34 to 0.35; I2=95%) (Figure 3). Significant heterogeneity was 
observed in both these measures.
Assessment of Safety and Complications  
The all-cause mortality (OR 0.99, 95% CI 0.07-14.75; I2=55%) 
for CBA and RFA respectively, Figure 4) and overall complications 
(7.5% vs. 6.9% for CBA and RFA respectively, (OR 1.06, 95% CI 
0.84-1.34; I2=31%) p=0.62; Figure 5a) were not significantly different. 
Among individual complications, CBA group had significantly lower 
groin site complications (1.35% vs. 1.74%, p=0.02; OR 0.60, 95% 
CI 0.38 - 0.93) and lower hemodynamically significant pericardial 
effusion/cardiac tamponade (0.56% vs. 1.37%, p=0.001), as compared 
to RFA respectively, higher rates of transient phrenic nerve injury 
(3% vs. 0.06%, p<0.001; OR 14.19, 95% CI 6.92-29.10) and 
persistent phrenic nerve injury (1.24% vs. 0.17%, p<0.001; OR 4.62, 
95% CI 1.97-10.81) a for CBA and RFA respectively. No significant 
difference was observed in stroke/thromboembolic events, major 
bleeding, and minor bleeding (Figure 5a and b). There were no 
reports of atrio-esophageal fistula or pulmonary vein stenosis.




Forest plot demonstrating procedural outcomes (randomized 
controlled trials only) in patients with atrial fibrillation 
undergoing cryoablation versus radiofrequency ablation
Supplementary 
Figure 4:
Forest plot demonstrating safety outcomes (randomized 
controlled trials only) - overall acute complications, groin site 
complications, transient and unresolved phrenic nerve injury 
and pericardial effusion/tamponade in patients with atrial 
fibrillation undergoing cryoablation versus radiofrequency 
ablation
Table 2: Baseline demographics of study population
Baseline Characteristic CBA RFA N Studies (n) RR or SWD (95% CI) Heterogeneity P for overall effect
P value I2 (%)
Age, yrs 59.2 60.1 3,138 11 -0.08 (-0.19 to 0.03) 0.01 53.3 0.14
Males, % 70.3% 70.5% 6,411 15 0.99 (0.97 to 1.03) 0.53 0 0.91
BMI 27.0 26.7 2,125 5 0.05 (-0.12 to 0.22) 0.007 71.6 0.58
LVEF, % 60.6% 60.0% 1,687 7 0.04 (-0.12 to 0.21) 0.02 57.8 0.58
LAD, mm 40.4 41.1 5,315 7 -0.18(-0.32 to -0.05) 0.01 61.6 0.008
Stroke/TIA, % 4.9% 7.7% 502 10 0.77 (0.63 to 0.93) 0.61 0 0.008
Hypertension, % 46.8% 48.1% 5,337 16 0.96 (0.90 to 1.03) 0.02 44.9 0.24
Diabetes, % 7.4% 6.5% 718 14 1.17 (1.01 to 1.36) 0.58 0 0.04
CAD, % 11.9% 13.6% 1,219 8 0.93 (0.82 to 1.04) 0.6 0 0.21
CBA=Cryoballoon ablation; RFA=Radiofrequency Ablation; RR=Relative Risk; SWD=Standardized Mean Difference; LVEF= Left Ventricular Ejection Fraction; BMI=Body-mass index; LAD= Left atrial 
diameter; TIA=Transient Ischemic Attack; CAD=Coronary artery disease
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and procedural characteristics of CBA with RFA in patients with 
paroxysmal AF. Our analysis suggests that CBA and RFA do not 
differ in terms of efficacy, procedural times, and overall complications. 
However, the analysis of individual complications demonstrated 
increased incidence of transient and persistent phrenic nerve injury 
and reduced hemodynamically significant pericardial effusion/cardiac 
tamponade and groin site complications with CBA as compared to 
RFA. No significant difference was observed in rates of major and 
minor bleeding and stroke/thromboembolic events. Interestingly 
there were no reports of atrio-esophageal fistula and pulmonary vein 
stenosis in both groups.
Freedom from Atrial Arrhythmia  
Our study demonstrated no difference between CBA and RFA 
in rates of freedom from atrial arrhythmias at 12 months follow-up, 
recurrent atrial arrhythmias and repeat ablations. Traditionally, point-
by-point ablation is expected to have gaps in ablation lines and hence 
more recurrence compared to the “single-shot” approach offered by 
CBA.21 Improved outcomes have been reported with RFA since the 
introduction of contact force-sensing catheter technology.22 However, 
this modality was not used consistently in our component studies 
and pooled together with traditional RFA (Table 1). Hanninen et al 
have previously reported a higher incidence of recurrent arrhythmia 
with CBA compared to RFA, especially atrioventricular nodal 
reentrant tachycardia.23 There have been two prior meta-analyses 
on this subject by Xu et al24 and Kabunga et al.25 We only included 
prospective and RCTs in our analysis as opposed to the prior meta-
analyses, and incorporated data from 7 additional contemporary trials 
since the last meta-analysis. Our data did not detect any evidence of 
superiority in efficacy with either of the two modalities. Even after 
restricting the analysis to RCTs, no difference in the primary efficacy 
versus 10.04%; OR: 1.19, 95% CI 0.57-2.52). Among individual 
complications, CBA group had significantly lower groin site 
complications (1.46% versus 3.76% for RFA group; OR: 0.41, 95% 
CI 0.18 – 0.95) and higher rates of transient phrenic nerve injury 
(3.1% versus 0 events in RFA group; OR 13.72, 95% CI 2.59 – 72.78) 
compared to RFA group. No significant difference was observed in 
unresolved phrenic nerve injury and significant pericardial effusion/
cardiac tamponade between the two groups (Supplementary 
appendix, Figure 4).
Analysis of Data from Trials Evaluating 2nd Generation CBA and 
Contact-Force RFA  
In the sub-analysis, evaluating 2nd generation CBA (CBA-2) and 
RFA using contact force-sensing (CF-RFA) catheters, only 2 trials 
were included.13,15 In these trials both groups had comparable rates 
of recurrent atrial arrhythmias (17.8% versus 17%; OR 1.07, 95% CI 
0.68 – 1.68) ( appendix, Figure 5).
Cryoablation was associated with similar total procedural time 
(Standard mean difference: 0.12; 95% CI: -0.76 - 0.99; I2=95%) and 
total fluoroscopy time (Standard mean difference: 0.10; 95% CI: 
-0.47 - 0.68; I2=89%) as RFA (Supplementary appendix, Figure 6).
The overall complications were similar in both the groups (10.6% 
versus 5.8%; OR 2.66, 95% CI 0.33 – 21.23, I2=83%). CBA group 
(2nd generation) had higher rates of transient phrenic nerve injury 
(9% versus 0 events in RFA group; OR 28.04, 95% CI 3.75 – 209.32) 
as compare to RFA group. No difference was observed in groin site 
complications (1.6% versus 3.2%; OR 0.48, 95% CI 0.14 – 1.62) 
between the two groups (Supplementary appendix, Figure 7).
Discussion
To the best of our knowledge, this is the largest meta-analysis 
of prospective and RCTs comparing the overall efficacy, safety 
Supplementary Figure 6: Forest plot demonstrating procedural outcomes in studies evaluating 2nd generation CBA catheter versus contact-sensing RFA catheter
Supplementary Figure 5: Forest plot demonstrating primary efficacy endpoints in studies evaluating 2nd generation CBA catheter versus contact-sensing RFA catheter
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subgroup analysis for RCTs only. A total of 12 trials reported this 
complication5-7,10,11,13,14,16-18,20 of which 3 were RCT’s.5-7 Number of 
transeptal punctures is a major factor contributing to development of 
cardiac tamponade or significant pericardial effusion.30 In 6 trials, the 
use of a single or double transeptal puncture was not specified5,7,11,13,14,18 
a double transeptal puncture approach was performed in 2 trials16,20 
and a single transeptal puncture for CBA and double for RFA was 
performed in 4 trials.6,10,12,17 The use of double transeptal puncture 
approach with RFA could have likely contributed to an increased 
incidence of cardiac tamponade in this group. However similar 
results were not observed in the subgroup analysis (RCT’s only). This 
could be potentially due to the use of double transeptal approach in 
majority patients in both CBA and RFA groups (although this was 
not specified in the RCTs).
Cryoablation was predominantly complicated by transient and 
unresolved phrenic nerve injury. One of the potential reasons for 
this association could be from the forward pressure exerted during 
CBA with the sheath for achieving a satisfactory circumferential 
seal around the target pulmonary vein. This motion likely pushes the 
atrium closer to surrounding structures including the phrenic nerve. 
Majority of phrenic nerve injuries were transient and spontaneously 
resolved with progression of approximately 1.3% injuries to persistent 
phrenic nerve injury at 12 months.31,32
Study Limitations  
Potential sources of bias in our study include combination of 1st and 
2nd generation CBA catheters into one group and different approaches 
of RFA in a single group (irrigated catheters, contact force-sensing 
catheters and duty-cycled phased RFA) and inclusion of data from 
prospective non-randomized trials. Additionally, there was a lack 
of uniformity in the participant trials in protocol for detection of 
recurrent AF; specifically, the follow-up periods, mode of arrhythmia 
detection, inclusion of patients on anti-arrhythmic therapy for 
assessment of efficacy outcomes. We tried to eliminate some of these 
biases by performing a sub-analysis of RCTs, which demonstrated 
results similar to original analysis with both groups showing similar 
efficacy, procedural characteristics, and complications profile.
Conclusions
Our analysis demonstrates that the two technologies for catheter 
ablation of AF are equivalent in efficacy, procedural characteristics 
and overall complications with higher rates of groin site complications 
and significant pericardial effusion/cardiac tamponade in the RFA 
group and phrenic nerve injury in the CBA group. Based on these 
data, we believe that currently, there is insufficient evidence to suggest 
superiority of one ablation strategy over the other for pulmonary vein 
isolation. Our study highlights the need for better technologies that 
would help us achieve a more efficient and durable pulmonary vein 
isolation.
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endpoints was observed between the two groups. Subgroup-analysis 
comparing the 2nd generation CBA with contact force-sensing RFA 
also demonstrated no significant difference in the primary efficacy 
end-points between the two groups (although results should be 
interpreted with caution in view of only 2 trials).
Procedural Characteristics  
Contrary to the findings from prior meta-analyses by Xu et al24 
and Kabunga et al,25 we found no significant difference in procedural 
characteristics including total procedural duration and fluoroscopy 
time. However, this needs to be interpreted with caution as a 
significant heterogeneity was observed in both these outcomes. The 
grouping of different techniques of RFA and different generations 
of CBA catheters could be a possible contributor to the significant 
heterogeneity observed in the participant studies.
Upon separate analysis of only the RCTs, there was reduced total 
fluoroscopic times in RFA group as compared to CBA group with 
no significant heterogeneity. The longer fluoroscopy times may be 
related to the impact of a learning curve for CBA. A steep learning 
curve with CBA has been shown in a large single center study even at 
a later stage in well-experienced center.26 In the trials comparing only 
2nd generation CBA catheters with contact-sense RFA catheters, no 
difference was observed, although significant heterogeneity persisted. 
This could possibly be due to local variations in experience and varied 
preferences in ablation technique.
Secondary Safety Outcomes and Associated Complications  
Overall complications rate observed was similar to registry data 
previously reported by Deshmukh et al27 and Cappato et al.3 Although 
no significant difference in overall complications was observed 
between the two groups, it is imperative to discuss the pattern of 
individual complications observed with the two approaches. Higher 
incidence of groin-site complications were seen with RFA as 
compared to CBA with the effect persisting in the sub-analysis with 
RCTs. This can potentially be explained by increased groin injuries, 
which may be caused by the two-sheath system often used with RFA 
(a radiofrequency catheter and a separate mapping catheter).28,29 
Unfortunately, the included studies did not mention the number of 
sheaths used during the procedure to better quantify the role of this 
effect.
Additionally an increased incidence of hemodynamically 
significant pericardial effusion/cardiac tamponade was observed 
in the RFA group. However no difference was observed in the 
Supplementary 
Figure 7:
Forest plot demonstrating safety outcomes – overall acute 
complications, groin site complications and transient phrenic 
nerve injury in studies evaluating 2nd generation CBA 
catheter and contact-sensing RFA catheter
Supplement 
Table 1: Summary of Egger’s and Begg’s test for publication bias
CBA versus RFA Egger’s test p-value Begg’s test p-value
Freedom from atrial fibrillation 0.83 1.00
Recurrent atrial arrhythmia 0.12 0.06
Repeat ablation 0.97 0.71
Overall complications 0.09 0.48
P value of <0.05 indicates publication bias
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